Efficient, accurate quantification of human antibodies in Cell Line Development, a comparison with BLI and SPR

By providing rapid and reliable titre measurements in a technology format that is accessible for all laboratories, the Amperia Redox Electrochemical Detection (RED) system is designed to remove analytical bottlenecks in cell line development (CLD) that are often associated with centralised equipment.

Accelerating decisions supports real-time optimisation and ultimately speeds up the selection of the most promising cell lines for therapeutic antibody production.

Agenus UK, a clinical-stage biopharmaceutical company focusing on immunotherapies for cancer, evaluated the performance of Amperia RED technology as part of a cell line development program.

• The accuracy of Amperia RED technology was of equal standard to that of the established BLI and SPR methods commonly found in central analytical laboratories.
• Amperia technology demonstrated a high correlation (R²=0.9) with BLI for antibody titre concentration when evaluated during a CLD campaign.
• Eight of the top 10 most productive clones ranked similarly based on antibody titre measured by Amperia RED and BLI.
• The Amperia system delivered results quickly, directly at-line to expedite decisions and alleviate analytical delays associated with transferring samples between labs.
• The study demonstrates the value of Amperia for efficient antibody titre measurement to support CLD campaigns in a real-world biopharmaceutical setting.